OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

In newly diagnosed GBM,

In a post hoc analysis of the EF-14 study, Optune + TMZ was associated with increased progression-free survival vs TMZ alone in patients 65 years of age and older1

  • This subgroup analysis included data from all 134 patients 65 years of age and older in the intent-to-treat population1
  • The analysis compared overall survival, progression-free survival, and safety between the two treatment arms: Optune + TMZ (n=89) vs TMZ (n=45)1
  • Median patient age and KPS were 69 years and 90%, respectively1
PFS data from a post-hoc analysis of elderly patients in the EF-14 study (Optune® + TMZ vs TMZ alone) PFS data from a post-hoc analysis of elderly patients in the EF-14 study (Optune® + TMZ vs TMZ alone)

In a post hoc analysis, Optune + TMZ was associated with improved OS vs TMZ alone in patients 65 years of age and older1

  • Elderly patients treated with Optune + TMZ experienced longer median OS (17.4 months) vs those using TMZ alone (13.7 months)1
  • OS with Optune + TMZ vs TMZ alone was higher at the 1-year analysis and remained higher at 2 years1
OS data from a post-hoc analysis of elderly patients in the EF-14 study (Optune® + TMZ vs TMZ alone) OS data from a post-hoc analysis of elderly patients in the EF-14 study (Optune® + TMZ vs TMZ alone)

Safety data in patients 65 years of age and older

  • No significant increase in systemic AEs in patients treated with Optune + TMZ (46%) vs TMZ alone (40%)1
  • SAEs were reported in 39% of patients treated with Optune + TMZ and in 33% of patients treated with TMZ alone1
  • None were considered related to treatment with Optune1
  • Grades 1 to 2 skin AEs were observed in 51% of patients using Optune1

AEs, adverse events; CI, confidence interval; GBM, glioblastoma; HR, hazard ratio; KPS, Karnofsky Performance Status; OS, overall survival; PFS, progression-free survival; SAEs, serious adverse events; TMZ, temozolomide.

Reference: 1. Ram Z, Zhu JJ. Poster presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II; June 22-29, 2020; Abstract 10636.

Results from the E-14 study post-hoc analysis on elderly patients

Learn about Optune + TMZ in elderly patients with histologically-confirmed, newly diagnosed GBM

View this PDF

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).